// App-Quantinova.ai

P511 : Baseline characteristics of ulcerative colitis patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01)

Researchers

Presenter

  • D. Wolf

Principal Investigators

  • B. Siegmund

  • G. Lichtenstein

  • S. Sebastian

  • C.A. Siegel

  • E. Louis

  • T. Haas

  • K. Nedd

  • S. Subramanian

  • H. Aguilar

  • L. Egan

  • C. Gasche

  • G. Doherty

  • A. Lobo

  • D. Spearman

  • A. Patel

  • R. Moparty

  • M. Brookes

  • X. Hebuterne

  • B. Moum

  • P. Dolin

Medical Centers

  • Atlanta Gastroenterology Associates, Atlanta, Georgia, United States

  • University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States

  • Charite - University Medicine Berlin, Campus Benjamin Franklin, Deptartment of Neurology, Berlin, Germany

  • Hull Royal Infirmary, Hull & East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom

  • Dartmouth-Hitchcock Medical Center, Gastroenterology, Lebanon, United States

  • CHU Liege, Liege, Belgium

  • Darm Praxis Salzburg, Salzburg, Austria

  • Infusion Associates, Grand Rapids, United States

  • Royal Liverpool University Teaching Hospital, Department of Gastroenterology, Z Link Unit, Liverpool, United Kingdom

  • Shreveport Endoscopy Center, Shreveport, LA, United States

  • NUI Galway, Department of Gastroenterology, Galway, Ireland

  • Medical University of Vienna, Vienna, Austria

  • St. Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland

  • Sheffield Teaching Hospitals NHS Foundation Trust, Academic Department of Gastroenterology, Sheffield, United Kingdom

  • San Antonio Military Medical Center, San Antonio, TX

  • Medical College of Wisconsin, Milwaukee, Wisconsin , United States

  • Spring Gastroenterology, Humble, TX, United States

  • The Royal Wolverhampton Hospital NHS, New Cross Hospital, Department of Gastroenterology, Wolverhampton, United Kingdom

  • CHU de Lille, Department of Gastroenterology, Lille, France

  • Oslo University, Department of Gastroenterology, Oslo, Norway

  • Takeda Development Centre Europe, Pharmacoepidemiology, London, United Kingdom

Locations

  • United States

  • Germany

  • United Kingdom

  • Belgium

  • Austria

  • Ireland

  • France

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • N/A


Study Design

  • Observational

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A